Search

Displaying results 1551 - 1560 of 4207 in total
  1. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  2. Drug

    Flurbiprofen

    go.drugbank.com/drugs/DB00712
    ApprovedInvestigational

    Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, os...

  3. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

  4. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.

  5. Drug

    Methaqualone

    go.drugbank.com/drugs/DB04833
    ApprovedIllicitWithdrawn

    The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … Clandestinely produced methaqualone is still seized by government agencies and police forces around the world.

  6. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764] … [F66] Perboric acid in the form of sodium perborate is approved by Health Canada since 2004 to be used as a disinfectant of medical instruments.

  7. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

  8. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

  9. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  10. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    It is not widely used as it has largely been replaced by newer drugs.